Longevity VectorY’s new ALS therapy moves forward after FDA clearanceBy adminDecember 3, 20250 FDA greenlights early-stage trial of VectorY’s first-in-class therapy targeting the core biology driving most ALS cases. Netherlands-based biotech VectorY Therapeutics…
